Novo's Danish facility expansion will free up production capacity
A DKK 5.4bn (USD 740m) investment into expanding capacity will help enable the Danish drugmaker’s R&D division become API self-sufficient, which will hopefully benefit the production of existing drugs.
.jpg)
by christopher due karlsson, translated by daniel pedersen
On Tuesday, Novo Nordisk announced it will expand its existing clinical API capacity in Bagsværd, a Copenhagen suburb, to improve the drugmaker’s capacity within research and development and clinical studies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk invests over USD 740m in Danish facility
For subscribers
.jpg&w=384&q=75)
